TherapeuticsMD (TXMD) Gross Margin (2011 - 2023)

TherapeuticsMD has reported Gross Margin for 13 years, with the latest figure at 100.0% in Q4 2023.

• For the quarter ending Q4 2023, Gross Margin changed 0.0% year-over-year to 100.0%; the trailing twelve-month figure through Dec 2023 stood at 92.47% (down 2622.0% YoY), and the FY2023 full-year result was 100.0%, up 200.0% from the prior year.
• Gross Margin for Q4 2023 stood at 100.0%, up from 100.0% in the prior quarter.
• The five-year high for Gross Margin was 2082.45% in Q1 2022, with the low at 100.0% in Q3 2023.
• Historically, Gross Margin has averaged 184.76% across 5 years, with a median of 81.28% in 2019.
• Annual changes were most pronounced in 2022 — Gross Margin soared 200604 bps — and 2023, when it sank 198245 bps.
• TherapeuticsMD's Gross Margin stood at 81.9% in 2019, then declined by 8 bps to 75.28% in 2020, then slipped by 1 bps to 74.64% in 2021, then surged by 34 bps to 100.0% in 2022, then changed by 0 bps to 100.0% in 2023.
• The last three Gross Margin figures came in at 100.0% (Q4 2023), 100.0% (Q3 2023), and 100.0% (Q2 2023), per Business Quant data.